# Cytokinetics, Incorporated (CYTK)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $8M  
**Price:** $69.27 (+3.28%)

> Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors. These small-molecule therapies target debilitating diseases where muscle performance is compromised or declining, including amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, hypertrophic cardiomyopathy, and chronic obstructive pulmonary disease. By specifically engineering compounds to enhance muscle function and contractility, Cytokinetics addresses impaired muscle function in cardiovascular and neuromuscular conditions. The company advances muscle-directed investigational medicines aimed at improving health outcomes for patients with serious diseases of cardiac and skeletal muscle dysfunction. Founded in 1997 and headquartered in South San Francisco, California, Cytokinetics leverages expertise in muscle biology to build a pipeline of sarcomere-directed therapies, positioning it as a key player in specialized biopharmaceutical innovation for muscle-related disorders.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $88M | — | -$612M | -$785M | — |
| 2024 | $18M | — | -$536M | -$590M | — |
| 2023 | $8M | — | -$496M | -$526M | — |
| 2022 | $95M | — | -$324M | -$389M | — |
| 2021 | $70M | — | -$186M | -$215M | — |
| 2020 | $56M | — | -$94M | -$127M | — |
| 2019 | $27M | — | -$99M | -$122M | — |
| 2018 | $32M | — | -$89M | -$106M | — |
| 2017 | $13M | — | -$113M | -$128M | — |
| 2016 | $106M | — | $19M | $16M | — |
| 2015 | $29M | — | -$37M | -$38M | — |
| 2014 | $47M | — | -$15M | -$15M | — |
| 2013 | $31M | — | -$34M | -$34M | — |
| 2012 | $8M | — | -$40M | -$40M | — |
| 2011 | $4M | — | -$48M | -$48M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.42B | $2.08B | -$660M | $123M | $246M |
| 2024 | $1.40B | $1.54B | -$135M | $95M | $620M |
| 2023 | $824M | $1.21B | -$386M | $113M | $639M |
| 2022 | $1.01B | $1.12B | -$108M | $66M | $650M |
| 2021 | $841M | $597M | $244M | $113M | $47M |
| 2020 | $534M | $420M | $113M | $83M | $46M |
| 2019 | $290M | $301M | -$11M | $36M | $45M |
| 2018 | $211M | $185M | $26M | $42M | $42M |
| 2017 | $295M | $185M | $110M | $125M | $32M |
| 2016 | $170M | $76M | $94M | $67M | $30M |
| 2015 | $115M | $47M | $69M | $65M | $15M |
| 2014 | $133M | $41M | $92M | $20M | — |
| 2013 | $83M | $29M | $54M | $20M | — |
| 2012 | $78M | $7M | $70M | $15M | — |
| 2011 | $53M | $5M | $48M | $19M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$510M | $25M | -$535M |
| 2024 | -$396M | $4M | -$400M |
| 2023 | -$414M | $1M | -$416M |
| 2022 | -$300M | $11M | -$311M |
| 2021 | -$143M | $49M | -$191M |
| 2020 | $9M | $11M | -$2M |
| 2019 | -$91M | $3M | -$94M |
| 2018 | -$101M | $889,000 | -$102M |
| 2017 | -$102M | $3M | -$105M |
| 2013 | -$8M | $542,000 | -$8M |
| 2012 | -$33M | $125,000 | -$34M |
| 2011 | -$46M | $443,000 | -$46M |
| 2010 | -$45M | $493,000 | -$45M |
| 2009 | $8M | $550,000 | $8M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CYTK)